Results 141 to 150 of about 75,992 (272)

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

A cDC1‐NK/T‐Malignant Cell Circuit Drives Immunogenic Remodeling Under PD‐1 Blockade in Gastric Cancer

Cancer Science, EarlyView.
Chemotherapy combined with nivolumab reshapes the gastric cancer tumor microenvironment (TME) and is accompanied by an enrichment of reduced cytotoxicity NK (RC‐NK) cells. Rather than acting as classical cytotoxic effectors, these RC‐NK cells appear to shape the TME by promoting an immunostimulatory circuit that engages adaptive immunity.
Takuya Nakatsuru, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Keita H. Nagaoka, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Yuko Ishii, Sai M. Pulukuri, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

Neutrophil‐Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo‐Immunotherapy

Cancer Science, EarlyView.
PD‐1 blockade combined with chemotherapy induces MHC‐II+ inflammatory neutrophils in gastric cancer, which engage in dynamic crosstalk with macrophages to remodel the tumor microenvironment toward a pro‐inflammatory state, thereby amplifying antitumor immune responses.
Keita H. Nagaoka, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Takuya Nakatsuru, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Sai M. Pulukuri, Yuko Ishii, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB–IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial

Cancer Science, EarlyView.
Kaplan–Meier survival curves comparing two‐cycle versus three‐cycle neoadjuvant sintilimab plus chemotherapy. (A) Disease‐free survival (DFS). (B) Overall survival (OS). CI, confidence interval; HR, hazard ratio; NR, not reached. ABSTRACT The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non‐small cell lung cancer (NSCLC ...
Miner Shao, Jie Yao, Lufeng Zhao, Ling Zhu, Baizhou Li, Lili Li, Bangyi Zhou, Yixin Zhang, Huiying Liu, Xiaoke Chen, Zuqun Wu, Zexin Chen, Junqiang Fan, Fuming Qiu   +13 more
wiley   +1 more source

Association Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with Nivolumab. [PDF]

Cancer Manag Res
Coskun A, Cavdar E, Sali S, Odabasi Bukun H, Sali M, Sahin AB, Deligonul A, Cubukcu E, Evrensel T.   +8 more
europepmc   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, Masayuki Hashimoto, Shoji Kitamura, Makoto Motoishi, Yuji Suzumura, Satoru Sawai, Yataro Daigo, Jun Hanaoka   +9 more
wiley   +1 more source

Future direction of systemic therapy for advanced renal cell carcinoma: lessons from final and extended follow-up data from the CheckMate 9ER trial. [PDF]

Transl Androl Urol
Ishihara H.
europepmc   +1 more source

Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers

Cancer Science, EarlyView.
Experimental BBN models link gut microbial metabolism and diet‐microbiome interactions to urothelial carcinogenesis, while circulating extracellular vesicle‐associated bacterial DNA signals may reflect tumor immune contexture and immune checkpoint inhibitor outcomes in urothelial and renal cell carcinoma.
Atsunari Kawashima, Kentaro Jingushi, Takuro Saito, Toshihiro Uemura, Akinaru Yamamoto, Nesrine Sassi, Hiromu Horitani, Shunsuke Inoguchi, Yuki Horibe, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Norio Nonomura   +12 more
wiley   +1 more source

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with <i>PD-L1</i> amplification: a case report. [PDF]

Ther Adv Med Oncol
Kodama H, Masuishi T, Ishizuka Y, Sakakida T, Honda K, Narita Y, Taniguchi H, Kadowaki S, Ando M, Hosoda W, Muro K.   +10 more
europepmc   +1 more source